- PR Newswire•18 days ago
NEW YORK, Feb. 8, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announces that Susanne Wilke PhD, Neurotrope's Chief Executive Officer, and Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer, are scheduled to present at the 2017 BIO CEO & Investor Conference being held on February 13th-14th, 2017 at the Waldorf Astoria Hotel in New York City. The Company's presentation will take place on Monday, February 13th, 2017 at 10:30am EST in the Conrad Room during the conference's CNS/Neurological Track. In addition, any investors attending the conference that wish to meet with Neurotrope's management can also contact our Director of Communications, Jeffrey Benison.
- PR Newswire•last monthNeurotrope Bioscience to Present at the Noble Financial Capital Markets' 13th Annual Investor Conference
NEW YORK, Jan. 27, 2017 /PRNewswire/ -- Neurotrope, Inc. (NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, is scheduled to present at the Noble Financial Capital Markets' 13th Annual NobleCON Conference, being held January 29-31, 2017 at the Boca Raton Resort in Boca Raton, Florida. A video and audio webcast of Neurotrope's presentation will be available at http://noble.mediasite.com/mediasite/Play/c54248f852db4353b8f007b16745782b1d and on the Company's web site at www.neurotropebioscience.com. Investors attending the conferences who would like to schedule a 1-on-1 meeting with Dr. Wilke may do so by contacting their Noble representative, or Jeffrey Benison of Neurotrope.
- PR Newswire•last month
NEW YORK, Jan. 12, 2017 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that its Board of Directors has approved a 1-for-32 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split was effective prior to the stock market opening on January 12, 2017. With the successful implementation of the reverse stock split and provided that the Company's common stock meets the NASDAQ minimum bid price requirement, the Company believes it will meet all requirements for listing Neurotrope's common stock on the NASDAQ Capital Market.
NTRP : Summary for NEUROTROPE INC COM USD0.0001(PO - Yahoo Finance
Neurotrope, Inc. (NTRP)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||17.50 - 19.25|
|52 Week Range||5.76 - 21.76|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|